NEWS

  • R&D
KORTUC’s clinical research result of unresectable recurrent uterine cervical cancer will be presented at ABS Annual Conference in Denver
  • R&D
Updated References
  • R&D
KORTUC’s therapy and its related basic research is to be presented by Dr. Navita Somaiah, Chief Principal Investigator of the ongoing pivotal KORTUC P2, at ARR 2022
  • CORPORATE
We participated in BIO Partnering at JPM etc
  • R&D
Results showing high efficacy and tolerable safety of Kortuc in several radioresistant cancer types were published in Molecular and Clinical Oncology. This shows KORTUC has potential to treat various types of cancer that are radioresistant
  • CORPORATE
KORTUC is to attend BIO CEO & Investor Conference in February
  • CORPORATE
KORTUC Inc. closed financing from SBI Investment to accelerate Pivotal Phase II study in UK and US
  • R&D
KORTUC Inc. started research collaboration with Okayama University on the tumor immunity by a novel radiosensitizer
  • CORPORATE
KORTUC is featured in the leading story in “Science Japan”
  • R&D
Results showing high efficacy of Kortuc in treating locally advanced or recurrent breast cancer were published in Molecular and Clinical Oncology. These predict a positive outcome of the current pivotal Phase 2 study